Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial

BACKGROUND: Transthyretin cardiac amyloidosis (ATTR‐CM), found in 6% to 15% of cohorts with heart failure with preserved ejection fraction, has long been considered a rare disease with poor prognosis. New treatments have made it one of the few directly treatable causes of heart failure. This study s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Morris M., Prasad, Mark, Burton, Yunwoo, Kolseth, Clinton M., Zhao, Yuanzi, Chandrashekar, Pranav, Nazer, Babak, Masri, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492973/
https://www.ncbi.nlm.nih.gov/pubmed/37522238
http://dx.doi.org/10.1161/JAHA.123.029705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492973/
https://www.ncbi.nlm.nih.gov/pubmed/37522238
http://dx.doi.org/10.1161/JAHA.123.029705

Ejemplares similares